The Mayo Clinic Comprehensive Cancer Center (MCCCC) enterprise site in Jacksonville, Florida invites applications for an open-rank faculty position for an innovative and accomplished leader in Artificial Intelligence, with experience in Computational Biology preferred, and their application in the basic, translational and clinical research programs within Radiation Oncology.

We seek an exceptional investigator (scientist and/or physician) with expertise in artificial intelligence (AI) and its application in basic and translational biology and clinical decision making. The successful candidate will play a central role in advancing a rapidly growing, multidisciplinary heavy particle program focused on discovery science, translational innovation, and clinical impact.

A key component of this role will be developing artificial intelligence tools within some of the areas below including, but not limited to:

Bioinformatics, Radiogenomics, and Integrated Multi-omics Analysis

Multimodality Image-Guided Targeting, Radiomics, and Adaptive Radiotherapy

Outcome Modeling and Clinical Decision Support

Medical Physics, Radiation Measurement, and Real-Time Response Assessment

Systems Analysis, Biophysical Analysis, and Translational Radiobiology

Strategic Role and Leadership Expectations

The investigator will:

Provide scientific expertise and have the opportunity for leadership roles in heavy particle therapy research program

Partner closely with the cancer center to develop next generation AI tools and models for the heavy particle therapy research program.

Develop innovative translational research programs that integrate radiobiology, imaging, computational science, and clinical data to advance precision heavy particle therapy.

Build multidisciplinary collaborations and research infrastructure that accelerate discovery and translation of heavy particle therapy innovations into clinical applications and trials.

Mentor trainees, junior faculty, and research staff within a collaborative and inclusive academic environment.

Participate in institutional initiatives aligned with Mayo Clinic and Mayo Clinic Comprehensive Cance Center’s vision to Cure, Connect, and Transform healthcare through transformative science.

The successful candidate will be a key driver in integrating artificial intelligence technologies into existing and emerging radiation oncology platforms, enabling novel approaches to heavy particle therapy.

Research Environment

Mayo Clinic and Mayo Clinic Comprehensive Cancer Center offer a highly collaborative and integrated academic medical center environment with expanding strengths in cell therapy, cancer immunotherapy, regenerative medicine, and translational science. Mayo Clinic and MCCCC have built a world-class research hub to transform cancer patient care through actionable target discovery and next-generation discovery and therapeutic platforms. These foundational platforms include Mayo Clinic Platform (www.mayoclinicplatform.org) which holds the fully digitized longitudinal patient records from 15M Mayo Clinic patients and 54M patients from across the nation and the globe with collaborating healthcare institutions, which facilitate research through development of longitudinal patient cohorts prior to and following disease diagnosis. Mayo Clinic has also developed very strong AI-driven discovery, translational, and clinical programs with exceptional “on premises” and cloud-based computational resources.

Faculty benefit from:

Established CAR-T and immune cell therapy programs with active clinical translation

State-of-the-art genome engineering and cell manufacturing infrastructure

Access to quantum computing

Dedicated AI research laboratory space

Robust disease-focused centers supporting both oncology and non-oncology therapeutic innovation

Dedicated institutional support for regulatory strategy, clinical trial development, and commercialization pathways

Cross-campus collaboration opportunities with Mayo Clinic sites in Minnesota and Arizona

Why Choose Mayo Clinic Comprehensive Cancer Center?

With 440 members and >1500 aligned cancer physicians working in six Cancer Research Programs (Cancer Prevention, Survivorship & Control; Cancer Risk Assessment, Early Detection & Interception; Cancer Genomics, Signaling, & Metastasis; Cancer Immunology & Immunotherapeutics; Novel Therapeutics & Therapeutic Modalities; Advanced Clinical Trials and Translational Sciences) and 15 Disease Groups focused on clinical trials, MCCCC is a global leader and represents the pinnacle of cancer care, research and education and training. Every year, across its three enterprise sites (Rochester, Minnesota; Phoenix and Scottsdale, Arizona; and Jacksonville, Florida), MCCCC physicians provide expert cancer diagnosis and treatment to more than 150,000 unique patients from across the nation and the globe.

The MCCCC Mission: To inspire hope and promote health and healing through integrated research, clinical practice, and education, centered around our primary value: the needs of the patient come first.

The MCCCC Vision: To be a global cancer authority: transforming cancer research and practice to assure that our discoveries, knowledge, and expertise are accessible to all, within and beyond our walls, at anyplace and anytime.

MCCCC Goals:

To cure cancers through translation of innovative transdisciplinary science to new means of prevention, early detection, interception, intervention, and unparalleled care delivery.

To transform cancer research and practice using category of one data platforms, digital technologies, artificial intelligence (AI), and intelligent automation, creating new models for community and patient engagement, and the conduct of research, clinical trials and patient-centered care delivery in clinical, home, and community settings.

To use Mayo Clinic Platform to engage patients and communities in our catchment areas and across the nation and the world in cancer research and distributed and decentralized clinical trials.

To educate, train, and mentor the next generation of cancer physicians, scientists, and leaders.

Over the past year, MCCCC has continued to achieve exceptional performance metrics, with high levels of cancer research funding (reporting $61.2M in annual peer-reviewed funding ($41.1M from NCI) and $98.7M in industry and non-peer reviewed funding). The Center currently has over 80 multi-investigator programmatic grants including 6 NCI Specialized Programs of Research Emphasis (SPORES): Myeloma, Ovarian Cancer, Breast Cancer, Liver/Hepatobiliary Cancers, Prostate Cancer, and Sarcoma. In 2025, clinical trial accrual has remained robust, reporting the Center’s highest accrual to therapeutic interventional trials: 2,624 (12% of newly registered cases), with 6,588 interventional accruals (30% of newly registered patients) and 10,367 non-interventional accruals. In 2025, MCCCC members published an exceptional number (1776) of peer-reviewed academic works, 24% of which were published in high impact journals.

Why Choose Mayo Clinic?

Mayo Clinic is a premier, integrated academic medical center consistently ranked among the top hospitals in the nation. All campuses are experiencing strategic growth in cancer immunotherapy, drug discovery & development, regenerative medicine, and translational discovery science.

We offer:

Competitive startup and sustained institutional support

Investment in team science and program-building initiatives

Access to a $1B+ annual research enterprise

Infrastructure for IND-enabling studies and early-phase clinical trials

Exceptional benefits, including retirement and pension programs

A culture that values innovation, inclusion, and transdisciplinary collaboration

Mayo Clinic is committed to creating an inclusive and equitable environment, recognizing that diverse research teams drive more innovative solutions to complex biomedical challenges.

Located in the state-of-the-art Duan Family Building on Mayo Clinic Florida's campus, advanced 360-degree proton gantries and carbon fixed beam enable enhanced targeting of hard-to-treat cancers. These technologies help Mayo Clinic physicians conduct integrated therapy planning and simulation in conjunction with radiation oncology treatments.

Other diagnostic and treatment modalities available in this space include:

An upright chair positioning system, which is the first of its kind in photon treatment

Multi-ion fixed beam room (commissioned with carbon in early 2028)

Synchrotron accelerator that can switch between three heavy particle energies in less than 20 seconds

3T MRI system

Photon linear accelerators for radiation therapy

To enhance the benefits of heavy particle therapy delivery, Mayo Clinic is partnering with a software development company to create an advanced treatment planning system that works with photon, proton and carbon ion therapies. This system, which is not typically available for most patients receiving radiation therapy, reduces the radiation dose sent to healthy tissue. It also provides real-time online adaptive treatment planning — adjusting each patient's plan daily based on tumor shrinkage or shifting.

Qualified candidates must hold a doctoral degree (Ph.D., M.D., M.D./Ph.D., Sc.D., or equivalent) in computational biology, artificial intelligence, radiation biology, biomedical engineering, or a related discipline.

Candidates should demonstrate:

Sustained extramural funding appropriate to academic rank (NIH K award or equivalent for Assistant Professor; R01-level funding or equivalent for Associate Professor or higher)

Evidence of scientific leadership and the ability to build collaborative, multidisciplinary research programs

A demonstrated commitment to mentorship, education, and fostering an inclusive academic culture

Preferred consideration will be given to candidates whose research bridges artificial intelligence with multiple domains—including quantitative imaging, radiogenomics, radiation measurement, and radiobiology—and who can translate computational or technological innovation into improved precision, personalization, and outcomes of radiation therapy.

Appointment level (Assistant, Associate, or Full Professor) will be commensurate with experience and years in rank, scholarly achievement, leadership experience, and funding record.